MondegarAI
CAXTON CORP

Q2 2024 · 13F-HR

CAXTON CORPholdings as filed

Filed 2024-08-14 · accession 0000919574-24-004535

$19.7M
Reported value
12
Positions
2024-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
98422E103XERSXERIS BIOPHARMA HOLDINGS INC$11.5M58.3%5,113,348CommonSOLE
76200L309RZLTREZOLUTE INC$5.7M28.7%1,318,967CommonSOLE
78462F103SPYSPDR S&P 500 ETF TR$1.0M5.15%1,869CommonSOLE
084670702BRK/BBERKSHIRE HATHAWAY INC DEL$417,0702.11%1,025CommonSOLE
52886X107LXEOLEXEO THERAPEUTICS INC$286,3311.45%17,851CommonSOLE
60255C885BRD1EURMIND MEDICINE INC$219,0591.11%30,383CommonSOLE
00370M103ABVXABIVAX SA$183,7600.93%13,900CommonSOLE
501976104KYTXKYVERNA THERAPEUTICS INC$172,3590.87%22,981CommonSOLE
608550208MTEMEURMOLECULAR TEMPLATES INC$157,3960.80%136,866CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$43,4650.22%43,465CommonSOLE
21077P108CNTXCONTEXT THERAPEUTICS INC$36,8990.19%18,403CommonSOLE
007002108TORCEURADICET BIO INC$21,1600.11%17,488CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.